Enveric Biosciences Inc. (ENVB)
| Bid | 1.36 |
| Market Cap | 2.65M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -36.3 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.41 |
| Volume | 556,668 |
| Avg. Volume (20D) | 177,835 |
| Open | 1.50 |
| Previous Close | 1.51 |
| Day's Range | 1.32 - 1.52 |
| 52-Week Range | 1.26 - 657.00 |
| Beta | undefined |
About ENVB
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosc...
Analyst Forecast
According to 1 analyst ratings, the average rating for ENVB stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 624.64% from the latest price.
2 weeks ago · businesswire.com
Enveric Biosciences Announces Closing of $5 Million Public OfferingCAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule ...
3 weeks ago · businesswire.com
Enveric Biosciences Announces Pricing of $5 Million Public OfferingCAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule ...
